Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) ROCE %: 13.62% (As of Dec. 2025)


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
81 GF Score
Price €4.52
GF Value €3.50
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co ROCE %?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 -2.59% 81 ROCE % is 13.62% as of Dec. 2025. GuruFocus rates FRA:I54 with a GF Score™ of 81/100 and a GF Value™ of €3.50 (Modestly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biocytogen Pharmaceuticals (Beijing) Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 13.62%.

Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Related Terms

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -27.63 -26.60 -13.40 7.25 10.73

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -13.94 0.61 13.96 9.41 13.62
FRA:I54
81GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co ROCE % Calculation

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=31.408/( ( (316.814 - 70.164) + (451.585 - 112.801) )/ 2 )
=31.408/( (246.65+338.784)/ 2 )
=31.408/292.717
=10.73 %

Biocytogen Pharmaceuticals (Beijing) Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=39.646/( ( (300.416 - 56.902) + (451.585 - 112.801) )/ 2 )
=39.646/( ( 243.514 + 338.784 )/ 2 )
=39.646/291.149
=13.62 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.62% mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a ROCE % of 13.62% as of Dec. 2025.
Is Biocytogen Pharmaceuticals (Beijing) Co's ROCE % too high?
Biocytogen Pharmaceuticals (Beijing) Co's current ROCE % is 13.62%. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's ROCE % compare to VRTX and REGN?
Biocytogen Pharmaceuticals (Beijing) Co's ROCE % of 13.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Biocytogen Pharmaceuticals (Beijing) Co's current ROCE % is 13.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.50, compared to a current price of €4.52 — trading 29.1% above its estimated fair value. The current ROCE % is 13.62%. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current ROCE % is 13.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €4.52 is trading 29.1% above its estimated GF Value™ of €3.50. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Modestly Overvalued.

Key valuation signals for FRA:I54:

  • ROCE %: 13.62%
  • GF Value™: €3.50 vs. price of €4.52 (29.1% above fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
81GF Score

Get the complete analysis for FRA:I54

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.52
Price
€3.50
GF Value